BNGO
Bionano Genomics, Inc.1.5700
+0.0300+1.95%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Routine users key to growth guide
Q&A gave light color on 2026's $30-33M revenue guide, pegging OGM installs comparable to 2025's 32 but staying mum on specifics to prioritize routine-user productivity. Management expects consumables volume to track that 5-16% growth as Q4 supply snags fade, noting routine users already grew YoY despite constraints. Upside rests on flipping 55 intending validators to the 60 validated cohort and boosting their output. The 47% CPT code hike for heme malignancies emerged as a prime catalyst. Routine users drive it all. Answers mostly echoed prepared remarks. Investors track routine traction next.
Key Stats
Market Cap
15.98MP/E (TTM)
-Basic EPS (TTM)
-12.77Dividend Yield
0%Recent Filings
8-K
Preliminary Q4 revenue at high end
Bionano Genomics released preliminary Q4 2025 results on January 12, 2026, with revenue of $7.8M-$8.0M, down 2-4% year-over-year but at guidance high end. Full-year revenue hit $28.4M-$28.6M amid 7-8% decline, yet installed 32 new OGM systems for a 387-system base. Cash stood at $29.6M. Results preliminary, subject to audit changes.
10-Q
Q3 FY2025 results
Bionano Genomics posted Q3 revenue of $7.4M, up 21% y/y from $6.1M yet down q/q (derived), with product sales climbing 15% y/y on stronger consumables and software while services rebounded post prior-year write-offs. Gross margins leaped to 46% from negative territory, thanks to cost cuts slashing R&D 40% y/y and SG&A 4% y/y; operating loss narrowed to $8.5M from $43.9M. Cash burn eased to $12.2M YTD versus $62.4M prior, ending with $3.1M cash, $18.5M investments, $10.3M restricted for $10.3M debentures (11%, due May 2026). Equity raises netted $22.4M YTD. Restructuring delivered. Geopolitical tensions hit Asia Pacific sales.
8-K
Q3 revenue up 21%, margins soar
Bionano Genomics reported Q3 2025 revenue of $7.4 million, up 21% from $6.1 million in Q3 2024, driven by 15% consumables growth and 7% more flowcells sold despite prior-year clinical write-downs. Gross margin hit 46% versus -139%, while operating expenses plunged 66% to $11.9 million; cash stood at $31.8 million. Revenue stabilized. Reiterates full-year 2025 guidance of $26-30 million.
8-K
Closes $10M offering
Bionano Genomics closed a $10M public offering on September 17, 2025, selling 4.925M shares (or pre-funded warrants) at $2.00 each with Series E (5-year) and Series F (18-month) warrants for 5M shares each at $2.00 exercise. Net proceeds hit ~$9.0M for working capital, yet dilution looms from potential $20M warrant exercises. Lockup bars new issuances for 30 days.
8-K
Q2 revenue dips, margins soar
Bionano Genomics reported Q2 2025 revenue of $6.7 million, down 13% from $7.8 million in Q2 2024 due to discontinued clinical services and fewer instrument sales, yet consumables and software rose 16% as routine OGM users drove growth. Gross margin surged to 52% from 33%, while operating expenses dropped 42% to $11.3 million, bolstering cash to $27.4 million. The strategy shift pays off. Company guides full-year revenue at $26-30 million and Q3 at $6.7-7.2 million, with cash lasting into Q1 2026 amid financing risks.
IPO
Website
Employees
Sector
Industry
AZTA
Azenta, Inc.
34.31-0.77
BDX
Becton, Dickinson and Company
196.39-3.70
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
NEO
NeoGenomics, Inc.
11.67-0.25
NTRA
Natera, Inc.
227.40-1.00
QGEN
Qiagen N.V.
45.01-0.43
TWST
Twist Bioscience Corporation
31.13+0.06
TXG
10x Genomics, Inc.
15.71-0.05
WGS
GeneDx Holdings Corp.
141.72-8.89